,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
dr. ohba sets the stage by showing that second line folfox response rate is 5% in cholangio t-dxd in her2+ cholangio rr 36.4% #asco22 
Leader, GI Oncology Unit @wilmotcancer. Researcher in #cachexia, #pancreaticcancer. Girl dad, @notredame alum, tweets opinion not medical advice